INO80E

Summary

INO80E (INO80 complex subunit E, HGNC:26905) is a protein-coding gene on chromosome 16p11.2, encoding INO80 complex subunit E (Q8NBZ0). Putative regulatory component of the chromatin remodeling INO80 complex which is involved in transcriptional regulation, DNA replication and probably DNA repair.

Involved in several processes, including chromatin remodeling; regulation of chromosome organization; and regulation of nucleobase-containing compound metabolic process. Located in nucleolus and nucleoplasm. Part of Ino80 complex.

Source: NCBI Gene 283899 — RefSeq curated summary.

At a glance

• GWAS associations: 14
• Clinical variants (ClinVar): 67 total — 2 pathogenic, 2 likely-pathogenic
• Phenotypes (HPO): 1
• MANE Select transcript: NM_173618

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26905
Approved symbol	INO80E
Name	INO80 complex subunit E
Location	16p11.2
Locus type	gene with protein product
Status	Approved
Aliases	FLJ90652
Ensembl gene	ENSG00000169592
Ensembl biotype	protein_coding
Entrez	283899

Gene structure

Transcript identifiers

Ensembl transcripts: 23 — 15 protein_coding, 4 retained_intron, 3 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000304516, ENST00000380503, ENST00000540562, ENST00000562291, ENST00000562441, ENST00000563040, ENST00000563197, ENST00000567065, ENST00000567254, ENST00000567705, ENST00000567987, ENST00000568043, ENST00000569957, ENST00000620599, ENST00000861522, ENST00000861523, ENST00000861524, ENST00000861525, ENST00000861526, ENST00000934710, ENST00000934711, ENST00000934712, ENST00000934713

RefSeq mRNA: 3 — MANE Select: NM_173618 NM_001304562, NM_001304563, NM_173618

CCDS: CCDS10665, CCDS76853

Canonical transcript exons

ENST00000563197 — 7 exons

Exon	Start	End
ENSE00001179043	30001414	30001530
ENSE00002624735	29996241	29996391
ENSE00003476755	30000758	30000836
ENSE00003483895	29996808	29996860
ENSE00003562548	29996547	29996617
ENSE00003609014	30005221	30005791
ENSE00003673648	30000929	30001040

Expression profiles

Bgee: expression breadth ubiquitous, 241 present calls, max score 96.81.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 42.0661 / max 287.1401, expressed in 1820 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
153579	35.0327	1819
153580	3.6677	1467
153575	1.3373	380
153577	1.1106	599
153581	0.5634	255
153576	0.2860	129
153578	0.0685	28

Top tissues by expression

255 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
granulocyte	CL:0000094	96.81	gold quality
right testis	UBERON:0004534	96.66	gold quality
left testis	UBERON:0004533	96.63	gold quality
right uterine tube	UBERON:0001302	95.86	gold quality
smooth muscle tissue	UBERON:0001135	95.73	gold quality
muscle layer of sigmoid colon	UBERON:0035805	95.60	gold quality
endocervix	UBERON:0000458	95.42	gold quality
body of uterus	UBERON:0009853	95.37	gold quality
lower esophagus muscularis layer	UBERON:0035833	95.34	gold quality
lower esophagus	UBERON:0013473	95.33	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	95.28	gold quality
right coronary artery	UBERON:0001625	95.16	gold quality
left uterine tube	UBERON:0001303	95.11	gold quality
ascending aorta	UBERON:0001496	95.07	gold quality
thoracic aorta	UBERON:0001515	95.05	gold quality
body of stomach	UBERON:0001161	95.03	gold quality
aorta	UBERON:0000947	94.90	gold quality
right adrenal gland	UBERON:0001233	94.90	gold quality
popliteal artery	UBERON:0002250	94.88	gold quality
tibial artery	UBERON:0007610	94.88	gold quality
transverse colon	UBERON:0001157	94.84	gold quality
metanephros cortex	UBERON:0010533	94.84	gold quality
right lobe of thyroid gland	UBERON:0001119	94.82	gold quality
rectum	UBERON:0001052	94.77	gold quality
mucosa of transverse colon	UBERON:0004991	94.73	gold quality
right adrenal gland cortex	UBERON:0035827	94.72	gold quality
descending thoracic aorta	UBERON:0002345	94.69	gold quality
left coronary artery	UBERON:0001626	94.68	gold quality
adenohypophysis	UBERON:0002196	94.66	gold quality
small intestine Peyer’s patch	UBERON:0003454	94.63	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.16
E-GEOD-106540	no	97.02

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

14 targeting INO80E, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4697-3P	99.89	67.09	1123
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-374C-5P	99.80	72.06	2910
HSA-MIR-655-3P	99.80	72.19	2909
HSA-MIR-4666B	99.64	68.69	1282
HSA-MIR-18A-3P	99.56	65.68	1092
HSA-MIR-6832-3P	99.52	70.44	1726
HSA-MIR-5693	99.24	66.67	1106
HSA-MIR-9851-5P	97.57	67.49	1067
HSA-MIR-6779-3P	97.51	65.82	789
HSA-MIR-938	97.41	68.28	656
HSA-MIR-592	96.59	67.59	817
HSA-MIR-541-3P	96.07	66.11	1271
HSA-MIR-654-5P	96.07	66.18	1280

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	ino80e	ENSDARG00000022939
mus_musculus	Ino80e	ENSMUSG00000030689
rattus_norvegicus	Ino80e	ENSRNOG00000019960
drosophila_melanogaster	CG18004	FBGN0033566

Protein

Protein identifiers

INO80 complex subunit E — Q8NBZ0 (reviewed: Q8NBZ0)

Alternative names: Coiled-coil domain-containing protein 95

All UniProt accessions (6): Q8NBZ0, H3BNM4, I3L0W8, I3L270, I3NI13, J3KNE2

UniProt curated annotations — full annotation on UniProt →

Function. Putative regulatory component of the chromatin remodeling INO80 complex which is involved in transcriptional regulation, DNA replication and probably DNA repair.

Subunit / interactions. Component of the chromatin remodeling INO80 complex; specifically part of a complex module associated with the N-terminus of INO80.

Subcellular location. Nucleus.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8NBZ0-1	1	yes
Q8NBZ0-2	2

RefSeq proteins (3): NP_001291491, NP_001291492, NP_775889* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR026678	INO80E	Family
IPR056515	INO80E_N	Domain

Pfam: PF24237

UniProt features (9 total): compositionally biased region 3, cross-link 2, chain 1, region of interest 1, coiled-coil region 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8NBZ0-F1	67.70	0.25

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 159, 171

Function

Pathways and Gene Ontology

Reactome pathways

8 pathways

ID	Pathway
R-HSA-5689603	UCH proteinases
R-HSA-5696394	DNA Damage Recognition in GG-NER
R-HSA-392499	Metabolism of proteins
R-HSA-5688426	Deubiquitination
R-HSA-5696398	Nucleotide Excision Repair
R-HSA-5696399	Global Genome Nucleotide Excision Repair (GG-NER)
R-HSA-597592	Post-translational protein modification
R-HSA-73894	DNA Repair

MSigDB gene sets: 125 (showing top): GOBP_CHROMOSOME_ORGANIZATION, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GOBP_TELOMERE_ORGANIZATION, GOBP_POSITIVE_REGULATION_OF_ORGANELLE_ORGANIZATION, GGAMTNNNNNTCCY_UNKNOWN, GOBP_REGULATION_OF_DNA_REPAIR, MONNIER_POSTRADIATION_TUMOR_ESCAPE_UP, GOBP_REGULATION_OF_TELOMERE_MAINTENANCE, chr16p11, GOBP_REGULATION_OF_CELL_CYCLE, GOBP_REGULATION_OF_RESPONSE_TO_STRESS, GOBP_DNA_STRAND_ELONGATION, GOBP_DNA_DAMAGE_RESPONSE, GOBP_POSITIVE_REGULATION_OF_DNA_REPAIR

GO Biological Process (14): telomere maintenance (GO:0000723), regulation of DNA replication (GO:0006275), DNA repair (GO:0006281), regulation of DNA repair (GO:0006282), DNA recombination (GO:0006310), chromatin remodeling (GO:0006338), regulation of chromosome organization (GO:0033044), positive regulation of DNA repair (GO:0045739), positive regulation of DNA-templated transcription (GO:0045893), regulation of embryonic development (GO:0045995), regulation of cell cycle (GO:0051726), regulation of DNA strand elongation (GO:0060382), positive regulation of telomere maintenance in response to DNA damage (GO:1904507), DNA damage response (GO:0006974)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (4): nucleoplasm (GO:0005654), nucleolus (GO:0005730), Ino80 complex (GO:0031011), nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-6 pathways:

Category	Pathways
Deubiquitination	1
Global Genome Nucleotide Excision Repair (GG-NER)	1
Post-translational protein modification	1
DNA Repair	1
Nucleotide Excision Repair	1
Metabolism of proteins	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
DNA metabolic process	3
regulation of DNA metabolic process	3
DNA repair	2
positive regulation of response to stimulus	2
nuclear lumen	2
telomere organization	1
DNA replication	1
DNA damage response	1
regulation of cellular response to stress	1
chromatin organization	1
regulation of organelle organization	1
chromosome organization	1
regulation of DNA repair	1
positive regulation of DNA metabolic process	1
DNA-templated transcription	1
regulation of DNA-templated transcription	1
positive regulation of RNA biosynthetic process	1
embryo development	1
regulation of multicellular organismal development	1
cell cycle	1
regulation of cellular process	1
DNA strand elongation	1
positive regulation of telomere maintenance	1
telomere maintenance in response to DNA damage	1
regulation of telomere maintenance in response to DNA damage	1
cellular response to stress	1
binding	1
cellular anatomical structure	1
intracellular membraneless organelle	1
nuclear chromosome	1
INO80-type complex	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

1898 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
INO80E	TFPT	P0C1Z6	783
INO80E	INO80D	Q53TQ3	754
INO80E	TMEM219	Q86XT9	668
INO80E	ASPHD1	Q5U4P2	667
INO80E	PAGR1	Q9BTK6	665
INO80E	TAOK2	Q9UL54	647
INO80E	HIRIP3	Q9BW71	627
INO80E	YPEL3	P61236	604
INO80E	C16orf54	Q6UWD8	596
INO80E	KCTD13	Q8WZ19	585
INO80E	SEZ6L2	Q6UXD5	583
INO80E	DOC2A	Q14183	577
INO80E	FIMP1	Q96LL3	571
INO80E	NFRKB	Q6P4R8	554
INO80E	INO80C	Q6PI98	545
INO80E	K7ENP7	K7ENP7	545

IntAct

125 interactions, top by confidence:

A	B	Type	Score
INO80E	YY1	psi-mi:“MI:0914”(association)	0.900
INO80E	MCRS1	psi-mi:“MI:0915”(physical association)	0.880
RUVBL1	ZNHIT1	psi-mi:“MI:0914”(association)	0.860
UCHL5	PSMD11	psi-mi:“MI:0914”(association)	0.840
YY1	ACTL6A	psi-mi:“MI:0914”(association)	0.830
INO80E	UCHL5	psi-mi:“MI:0915”(physical association)	0.820
RUVBL2	ZNHIT1	psi-mi:“MI:0914”(association)	0.810
INO80E	INO80B	psi-mi:“MI:0914”(association)	0.790
INO80E	TFPT	psi-mi:“MI:0914”(association)	0.790
YY1	TFPT	psi-mi:“MI:0914”(association)	0.740
INO80E	SDCBP	psi-mi:“MI:0915”(physical association)	0.720
GEM	INO80E	psi-mi:“MI:0915”(physical association)	0.720
SDCBP	INO80E	psi-mi:“MI:0915”(physical association)	0.720
INO80E	GEM	psi-mi:“MI:0915”(physical association)	0.720
RUVBL2	POLR3A	psi-mi:“MI:0914”(association)	0.640
RUVBL1	POLR3A	psi-mi:“MI:0914”(association)	0.640
INO80E	ACTL6A	psi-mi:“MI:0914”(association)	0.640
BCL7A	ARID1A	psi-mi:“MI:0914”(association)	0.640
LRRC46	TFPT	psi-mi:“MI:0914”(association)	0.640

BioGRID (154): INO80E (Two-hybrid), INO80E (Two-hybrid), INO80E (Two-hybrid), INO80E (Two-hybrid), INO80E (Two-hybrid), INO80E (Two-hybrid), INO80E (Two-hybrid), INO80E (Two-hybrid), INO80E (Two-hybrid), INO80E (Affinity Capture-MS), INO80E (Affinity Capture-MS), INO80E (Affinity Capture-MS), ACTR5 (Co-fractionation), INO80 (Co-fractionation), INO80E (Co-fractionation)

ESM2 similar proteins: A5D962, A6NKL6, A7UKY7, E9Q1P8, O15209, O35615, O75081, O95936, P0C7U0, P35568, P39881, P56270, P56671, P70298, P81122, Q15742, Q29RS4, Q5NBY9, Q5R3F8, Q5TC79, Q5TJE2, Q61127, Q62985, Q68FM6, Q6AY75, Q6AYH2, Q6NS60, Q7Z5L9, Q86UZ6, Q8BID6, Q8BSN5, Q8BZ97, Q8CDC7, Q8IX07, Q8NBZ0, Q8TF61, Q91ZM2, Q96C00, Q96JB3, Q99NA2

Diamond homologs: Q29RS4, Q6AYH2, Q8NBZ0

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
INO80E	“form complex”	“INO80 complex”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 70 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Global Genome Nucleotide Excision Repair (GG-NER)	8	81.2×	4e-12
Formation of the canonical BAF (cBAF) complex	5	70.5×	4e-07
DNA Damage Recognition in GG-NER	9	57.1×	4e-12
Nucleotide Excision Repair	8	50.8×	2e-10
Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF)	5	50.8×	2e-06
UCH proteinases	13	35.9×	6e-15
Regulation of MITF-M-dependent genes involved in pigmentation	5	29.5×	3e-05
Deubiquitination	10	27.6×	2e-10

GO biological processes:

GO term	Partners	Fold	FDR
positive regulation of telomere maintenance in response to DNA damage	11	202.6×	4e-22
regulation of DNA strand elongation	11	189.9×	6e-22
regulation of chromosome organization	11	168.8×	3e-21
regulation of DNA replication	12	72.1×	7e-18
positive regulation of DNA repair	12	70.5×	7e-18
regulation of embryonic development	11	59.6×	2e-15
DNA recombination	10	55.2×	8e-14
regulation of G0 to G1 transition	5	55.2×	9e-07

Disease & clinical

Clinical variants and AI predictions

ClinVar

67 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	2
Uncertain significance	53
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (4)

Variant ID	HGVS	Classification
1706497	GRCh37/hg19 16p11.2(chr16:29432212-30177807)x1	Pathogenic
523254	GRCh37/hg19 16p11.2(chr16:29592783-30190568)	Pathogenic
145958	GRCh38/hg38 16p11.2(chr16:29609368-30179188)x3	Likely pathogenic
223112	NC_000016.10:g.(?29685652)(30180586_?)dup	Likely pathogenic

SpliceAI

1709 predictions. Top by Δscore:

Variant	Effect	Δscore
16:29996392:G:GG	donor_gain	1.0000
16:29996806:A:AG	acceptor_gain	1.0000
16:29996807:G:GG	acceptor_gain	1.0000
16:30000756:A:AG	acceptor_gain	1.0000
16:30000757:G:GG	acceptor_gain	1.0000
16:30000834:GAG:G	donor_gain	1.0000
16:29996387:TCTAC:T	donor_gain	0.9900
16:29996807:GTTTC:G	acceptor_gain	0.9900
16:30000753:CACA:C	acceptor_loss	0.9900
16:30000754:ACAG:A	acceptor_loss	0.9900
16:30000756:A:C	acceptor_loss	0.9900
16:30000757:G:GA	acceptor_loss	0.9900
16:30000757:GA:G	acceptor_gain	0.9900
16:30000757:GACTC:G	acceptor_gain	0.9900
16:30000833:AGAGG:A	donor_loss	0.9900
16:30000834:GAGG:G	donor_loss	0.9900
16:30000836:GGTGA:G	donor_loss	0.9900
16:30000837:G:GG	donor_gain	0.9900
16:30000837:GTGAG:G	donor_loss	0.9900
16:30000838:T:A	donor_loss	0.9900
16:30000923:CTCCA:C	acceptor_loss	0.9900
16:30000924:TCCA:T	acceptor_loss	0.9900
16:30000926:CA:C	acceptor_loss	0.9900
16:30000927:AGG:A	acceptor_loss	0.9900
16:30000928:G:T	acceptor_loss	0.9900
16:30000928:GGAA:G	acceptor_gain	0.9900
16:30001036:GCTCG:G	donor_gain	0.9900
16:29996388:CTACG:C	donor_loss	0.9800
16:29996389:TAC:T	donor_gain	0.9800
16:29996390:ACGT:A	donor_loss	0.9800

AlphaMissense

1553 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:29996363:T:C	L18P	1.000
16:29996367:G:C	K19N	1.000
16:29996367:G:T	K19N	1.000
16:29996375:T:C	L22P	1.000
16:29996384:T:C	L25P	1.000
16:29996572:T:C	L36P	1.000
16:29996596:T:C	L44P	1.000
16:29996809:T:C	F52L	1.000
16:29996811:C:A	F52L	1.000
16:29996811:C:G	F52L	1.000
16:29996813:T:C	L53P	1.000
16:29996816:T:C	L54P	1.000
16:29996822:G:C	R56P	1.000
16:29996825:T:C	L57P	1.000
16:29996365:A:G	K19E	0.999
16:29996369:G:C	R20P	0.999
16:29996549:G:C	E28D	0.999
16:29996549:G:T	E28D	0.999
16:29996559:T:C	F32L	0.999
16:29996560:T:C	F32S	0.999
16:29996561:C:A	F32L	0.999
16:29996561:C:G	F32L	0.999
16:29996580:G:C	A39P	0.999
16:29996608:G:C	R48P	0.999
16:29996610:G:C	D49H	0.999
16:29996611:A:C	D49A	0.999
16:29996611:A:T	D49V	0.999
16:29996613:A:G	K50E	0.999
16:29996615:G:C	K50N	0.999
16:29996615:G:T	K50N	0.999

dbSNP variants (sampled 300 via entrez): RS1000336416 (16:30000640 C>T), RS1000638423 (16:29994476 A>G), RS1000680812 (16:29998616 A>G), RS1000793929 (16:30000404 T>C), RS1001178089 (16:29998747 C>T), RS1001278787 (16:29998006 A>G), RS1001378835 (16:30005553 C>A,T), RS1001508254 (16:30001116 G>A,T), RS1001604345 (16:30006051 C>T), RS1001640977 (16:29995506 G>A), RS1001981804 (16:30000691 G>A), RS1002350360 (16:30004742 G>C,T), RS1002415848 (16:30004292 C>T), RS1002688696 (16:29999139 C>T), RS1003013538 (16:29998842 G>A)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (2): autism spectrum disorder (MONDO:0005258), obesity disorder (MONDO:0011122)

Orphanet (3): Obesity due to melanocortin 4 receptor deficiency (Orphanet:71529), NON RARE IN EUROPE: Autism (Orphanet:106), NON RARE IN EUROPE: Non rare obesity (Orphanet:521399)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0001513	Obesity

GWAS associations

14 associations (top):

Study	Trait	p-value
GCST002539_82	Schizophrenia	5.000000e-11
GCST002783_135	Body mass index	2.000000e-06
GCST002783_320	Body mass index	2.000000e-06
GCST004495_20	BMI (adjusted for smoking behaviour)	2.000000e-09
GCST004495_21	BMI (adjusted for smoking behaviour)	6.000000e-06
GCST004497_117	Body mass index (joint analysis main effects and smoking interaction)	3.000000e-08
GCST004499_21	BMI in non-smokers	3.000000e-07
GCST004521_236	Autism spectrum disorder or schizophrenia	4.000000e-10
GCST004946_142	Schizophrenia	8.000000e-13
GCST006803_23	Schizophrenia	6.000000e-13
GCST007293_15	Body fat distribution (arm fat ratio)	6.000000e-06
GCST007293_81	Body fat distribution (arm fat ratio)	4.000000e-08
GCST007611_22	Chronic obstructive pulmonary disease or high blood pressure (pleiotropy)	7.000000e-09
GCST010703_269	Brain morphology (MOSTest)	4.000000e-13

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index
EFO:0004318	smoking behavior
EFO:0004341	body fat distribution
EFO:0004346	neuroimaging measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

29 total (human), top 29 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
(+)-JQ1 compound	decreases expression	3
Particulate Matter	increases abundance, increases expression, affects cotreatment	2
FR900359	affects phosphorylation	1
bisphenol A	decreases expression	1
lead acetate	increases expression	1
perfluorooctanoic acid	decreases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, increases expression	1
coumarin	decreases phosphorylation	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	affects binding, increases reaction	1
perfluoro-n-nonanoic acid	decreases expression	1
perfluorohexanesulfonic acid	decreases expression	1
ICG 001	decreases expression	1
jinfukang	increases expression	1
3-(2-hydroxy-4-(2-methylnonan-2-yl)phenyl)cyclohexan-1-ol	decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	decreases expression	1
Air Pollutants	increases abundance, increases expression	1
Ethanol	affects cotreatment, increases abundance, increases expression	1
Benzo(a)pyrene	affects methylation	1
Coumestrol	increases expression, affects cotreatment	1
Gasoline	affects cotreatment, increases abundance, increases expression	1
Hydralazine	increases expression, affects cotreatment	1
Polycyclic Aromatic Hydrocarbons	affects cotreatment, increases abundance, increases expression	1
Smoke	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Valproic Acid	affects cotreatment, increases expression	1
Aflatoxin B1	increases methylation	1
Copper Sulfate	decreases expression	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_SS61	HAP1 INO80E (-) 1	Cancer cell line	Male
CVCL_SS62	HAP1 INO80E (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT01302964	PHASE3	COMPLETED	Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
NCT01706523	PHASE3	TERMINATED	Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
NCT01825798	PHASE3	COMPLETED	Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)
NCT01972074	PHASE3	COMPLETED	Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder
NCT02985749	PHASE3	COMPLETED	A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder
NCT03197922	PHASE3	COMPLETED	Treatment of Encopresis in Children With Autism Spectrum Disorders
NCT03504917	PHASE3	TERMINATED	A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension
NCT03553875	PHASE3	TERMINATED	Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions
NCT03640156	PHASE3	COMPLETED	Modulating Socially Adaptive Mirror System Functioning in Autism by Oxytocin
NCT03715153	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.
NCT03715166	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder
NCT04233502	PHASE3	WITHDRAWN	Efficacy and Safety of Slenyto for Insomnia in Children With ASD
NCT04578756	PHASE3	COMPLETED	Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
NCT04623398	PHASE3	COMPLETED	Effect of Lithium in Patients With Autism Spectrum Disorder and Phelan-McDermid Syndrome (SHANK3 Haploinsufficiency)
NCT04725383	PHASE3	TERMINATED	Amitriptyline for Repetitive Behaviors in Autism Spectrum Disorders
NCT05212493	PHASE3	COMPLETED	The Effects of Medical Cannabis in Children With Autistic Spectrum Disorder
NCT05361707	PHASE3	UNKNOWN	Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances
NCT05439616	PHASE3	COMPLETED	Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD
NCT06229210	PHASE3	RECRUITING	Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder